$CCEP

Coca-Cola Europacific Partners (ENXTAM:CCEP) Stock Trades Below Fair Value On Cash Flow

Coca-Cola Europacific Partners (CCEP) trades at €89.40, below its intrinsic value based on discounted cash flow analysis. The company generated €2.0b in free cash flow over the past year, with projections suggesting steady growth. Analysts debate whether the stock is undervalued by 7% or overvalued by 11% due to strategic moves and regulatory pressures.

Original reporting
Published Sep 23, 2026, 4:29 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 6:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Coca-Cola Europacific Partners (ENXTAM:CCEP) Stock Trades Below Fair Value On Cash Flow — source image
Decision brief

The 30-second read

$CCEPNeutralLow
01

Why it matters

The piece reiterates existing data but frames CCEP as undervalued, offering a modest trade idea.

02

Market read

Provides a valuation perspective for a single European consumer‑goods stock; limited broader market impact.

03

What to watch

Potential impact of sugar taxes and changing consumer preferences not fully captured in the model.

Relevance 4/10Novelty 2/10Timing: none

Background

Simply Wall St offers a fundamental analysis of CCEP, focusing on cash‑flow based valuation.

Company-level read

Ticker impact

$CCEPNeutralMedium confidence
Context

The article provides a fresh DCF valuation suggesting CCEP is significantly undervalued relative to its €89.40 price.

Expected impact

Modest upside of 5‑10% over the next few weeks if investors adopt the valuation view.

Evidence & confidence

Valuation is model‑based and not backed by new corporate actions; price reaction depends on investor conviction.

Market effects

Highlights valuation considerations for other beverage bottlers and distributors.

Limited to European consumer‑goods markets.

Low; does not affect broader market trends.

Counterpoint

Some investors may argue the DCF assumptions are optimistic given regulatory headwinds.

Key entities

  • Coca‑Cola Europacific Partners

    European bottler and distributor of Coca‑Cola beverages.

Related articles

$CCEPMed

UBS reiterates Neutral rating on Coca-Cola Europacific Partners stock

UBS reiterated a Neutral rating on Coca-Cola Europacific Partners (CCEP) with a $107.00 price target, citing 5.4% Q3 organic sales growth forecast. The stock trades at $100.50, above InvestingPro’s Fair Value estimate. UBS expects growth in Europe and Asia Pacific, with potential for raised full-year revenue guidance. CCEP reported H1 2026 revenue of EUR 10.7 billion, up 6.1%, and EPS growth of 10.6%. Analysts have mixed views on its valuation and outlook.

Low

Coca Cola Europacific Partners (ENXTAM:CCEP) Board Exit Leaves Its Undervalued Case In Focus

Coca-Cola Europacific Partners (CCEP) is under scrutiny after independent non-executive director Nathalie Gaveau resigned, prompting a review of board roles. The company's share price is €88.3, down 6.26% over the past month but up 17.42% year-to-date and 116.77% over five years. Analysts suggest CCEP is 8% undervalued with a fair value of €95.68, citing strong long-term growth prospects in emerging markets and digital investments.

$CCEPHigh

Transactions in Own Shares

Coca-Cola Europacific Partners (CCEP) repurchased 403,748 ordinary shares from 7 to 11 September 2026, totaling approximately $43.5 million (USD) and £31.2 million (GBP) on US and London trading venues, respectively. The shares were bought as part of the company's EUR 1 billion share buyback program announced in February 2026. The repurchased shares will be cancelled.

$CCEPHigh

CCEP slips as a fresh Wall Street downgrade adds to valuation concerns

Coca-Cola Europacific Partners (CCEP) fell 3.1% after J.P. Morgan re-initiated coverage with an Underweight rating and a $92 price target, citing valuation concerns and potential slowdown in volume growth. The stock has faced scrutiny due to its premium valuation, despite solid first-half 2026 results. Institutional investors have recently adjusted their positions in CCEP.

$CCEPMedAI 8/10

CCEP (CCEP) Q2 2026 Earnings Call Transcript

Coca-Cola Europacific Partners (CCEP) reported Q2 2026 results on a half-year basis: revenue EUR 10.7B (+6.1%), operating profit EUR 1.5B (+8.1%), operating margin 13.8% (+30 bps), and diluted EPS EUR 2.20 (+10.6%). Free cash flow was EUR 435M in H1; management reaffirmed full-year FCF target of at least EUR 1.7B and completed EUR 600M of a EUR 1B buyback. Risks include Middle East commodity volatility.